NCT05428215View on ClinicalTrials.gov

Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Gender Dysphoria
Interventions
DRUG

17beta Estradiol

Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration

Trial Locations (1)

04102

Maine Medical Center, Portland

Sponsors

Lead Sponsor

MaineHealth
All Listed Sponsors
lead

MaineHealth

OTHER